NL-OMON22777招募中不适用
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (Zevalin) in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77).
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age >= 60 years old;
- •2. WHO performance status of 0-2;
排除标准
- •1. Hypoplastic bone marrow at biopsy;
- •2. Prolonged pancytopenia during induction chemotherapy and delayed courses during R-CHOP induction (more than two weeks delay due to insufficient bone marrow reserve);
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (Zevalin) in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77) - HOVON 77patients with diffuse Large B-Cell lymphoma, CD20-positiveMedDRA version: 8.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSEUCTR2005-003796-20-BEHOVON Foundation37
尚未招募
不适用
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.follicular lymphoma/folliculair lymfoomfirst line therapy/eerstelijnsbehandeling90Y-ibritumomab tiuxetanNL-OMON28762Vumc, hematology department31
已完成
2 期
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (*Zevalin*) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.NL-OMON33142Vrije Universiteit Medisch Centrum31
进行中（未招募）
不适用
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.follicular B cell NHLMedDRA version: 9.1Level: LLTClassification code 10024914Term: Low grade lymphomaMedDRA version: 9.1Level: LLTClassification code 10003899Term: B-cell lymphomaEUCTR2009-012944-17-NLVUMC
已完成
1 期
A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)HypertensionNCT01104545Merck Sharp & Dohme LLC24